Genetically modified interferon: is there a consensus yet?

Geoffrey Haydon, David Mutimer

Research output: Contribution to journalArticle

3 Citations (Scopus)


The treatment of patients with chronic hepatitis C virus infection has evolved during the last decade from interferon monotherapy to combination therapy with interferon and ribavirin. National and international guidelines recommend either 6 or 12 months of interferon/ribavirin combination therapy depending on the pre-treatment virological status of the patient. However, the choice for second-line treatment of patients who do not achieve sustained viral clearance with combination therapy has yet to be defined. This commentary examines previously published studies of the use of consensus interferon for hepatitis C virus infected patients. The characteristics of the treated populations and response to treatment are examined. The current and potential roles for this type of interferon in the treatment of hepatitis C virus infection are considered.
Original languageEnglish
Pages (from-to)471-473
Number of pages3
JournalEuropean Journal of Gastroenterology & Hepatology
Publication statusPublished - 1 Jan 2002


Dive into the research topics of 'Genetically modified interferon: is there a consensus yet?'. Together they form a unique fingerprint.

Cite this